Introduction
ECM mineralization in bones and teeth is a genetically regulated process. In humans, genetic mutations may lead to a variety of diseases affecting ECM mineralization in skeletal and dental tissues, which include X-linked hypophosphatemia, hypophosphatasia, rickets, and some forms of osteogenesis/dentinogenesis imperfecta (Tanaka and Deluca, 1974; Whyte, 1994; Nesbitt et al., 1999; Glorieux et al., 2002; Goldberg et al., 2008) . Although considered as a critical physiological process, the molecular mechanism of ECM mineralization is still not fully understood. Identification of novel genetic regulators of this process and elucidation of their modes of action may lead to effective interventions for genetic diseases associated with abnormal skeletal mineralization.
Our current understanding suggests that skeletal and dental ECM mineralization can be attributed to a large extent to the unique promineralization environment of these hard tissues. Two mineral ions, P i and calcium, when present at physiological concentrations, will promote apatitic mineral crystal growth within and between newly synthesized collagen fibrils in the skeletal ECM (Murshed et al., 2005) . Apart from the mineral ions themselves, extracellular levels of mineralization inhibitors can also affect ECM mineralization (Luo et al., 1997; Okawa et al., 1998; Ho et al., 2000; Murshed et al., 2004) . For example, >40 yr ago, it was shown that PP i , a chemical derivative of P i , can potently inhibit the mineralization process (Fleisch and Bisaz, 1962; Terkeltaub, 2001 ). More recently, it has been shown that matrix gla protein (MGP), a small extracellular protein, prevents ECM mineralization in the cartilage and vascular tissues (Luo et al., 1997; Murshed et al., 2004) .
Type 1 collagen, a scaffolding ECM protein, and tissuenonspecific alkaline phosphatase (ALPL [alkaline phosphatase, liver/bone/kidney]), an enzyme required for the cleavage of PP i in the bone matrix, are both necessary for normal bone mineralization (Waymire et al., 1995; Hessle et al., 2002; Murshed et al., 2005) . We recently demonstrated the importance of these A deletion mutation called fro (fragilitas ossium) in the murine Smpd3 (sphingomyelin phospho diesterase 3) gene leads to a severe skeletal dys plasia. Smpd3 encodes a neutral sphingomyelinase (nSMase2), which cleaves sphingomyelin to generate bioactive lipid metabolites. We examined endochondral ossification in embryonic day 15.5 fro/fro mouse embryos and observed impaired apoptosis of hypertrophic chondro cytes and severely undermineralized cortical bones in the developing skeleton. In a recent study, it was suggested that nSMase2 activity in the brain regulates skeletal devel opment through endocrine factors. However, we detected Smpd3 expression in both embryonic and postnatal skel etal tissues in wildtype mice. To investigate whether nSMase2 plays a cellautonomous role in these tissues, we examined the in vitro mineralization properties of fro/fro osteoblast cultures. fro/fro cultures mineralized less than the control osteoblast cultures. We next generated fro/fro;Col1a1Smpd3 mice, in which osteoblastspecific expression of Smpd3 corrected the bone abnormalities observed in fro/fro embryos without affecting the carti lage phenotype. Our data suggest tissuespecific roles for nSMase2 in skeletal tissues.
embryos and adult mice using skeletal preparations, microcomputed tomography (micro-CT), and histology/histomorphometric analysis. We demonstrate here that the fro mutation affects bone ECM mineralization in both embryos and in adult mice and that there is a delay of apoptosis in the hypertrophic chondrocytes in the developing fro/fro skeleton. We also show that osteoblast-specific expression of the Smpd3 transgene in fro/fro;Col1a1-Smpd3 mice completely rescues the bone mineralization defects, whereas the cartilage phenotype that appears during early skeletal development remains unaffected. Our work establishes the fro mutation as the sole cause of skeletal abnormalities in the fro/fro mice and suggests a cell-autonomous, tissue-specific role for nSMase2 in the developing skeleton.
Results
Impaired bone mineralization in fro/fro mice fro/fro neonates are characterized by a shortened body stature with skeletal abnormalities (Aubin et al., 2005) . As shown by the skeletal preparations of the newborn mice, both flat (intramembranous) and long (endochondral) bones are affected-the parietal suture was poorly mineralized, whereas both fore-and hind limbs were severely bent in the fro/fro mutants (Fig. 1,  A and B) . Further analysis by micro-CT revealed a reduction of mineralized tissue in the flat bones of the skull and alveolar bones in the jaw (Fig. 1 C) .
To further confirm that the observed decrease in mineralized tissue was attributable purely to a mineralization defect, we examined wild-type (WT) and mutant mice for the presence of excess osteoid, the proteinaceous matrix secreted by osteoblasts, which subsequently becomes mineralized. Histological analysis of the parietal bones in the skullcap of 2-d-old fro/fro mice revealed a severely hypomineralized matrix at the suture ( Fig. 1 D, top) . Also, there was a marked reduction of mineralization in the alveolar bones from these mice (Fig. 1 D, bottom) . By 1 mo of age, the trabecular bones of fro/fro mice showed an increase of 5% in osteoid volume over total bone volume as measured by histomorphometry (Fig. 1, E and F) . Similarly, there was a significant increase in the osteoid surface in the fro/fro bones (Fig. 1 G) . These results indicate that osteoid ECM is indeed deposited but is not efficiently mineralized. None of these skeletal abnormalities were seen in +/fro mice; therefore, we used these mice as controls for our subsequent in vivo analyses.
The fro mutation abolishes nSMase2 activity but does not affect its membrane localization
The fro mutation causes a deletion in Smpd3, resulting in a replacement of the last 33 amino acids of nSMase2. In a previous study, reduced nSMase activity was reported in skin samples collected from fro/fro mice (Aubin et al., 2005) . This reduced enzymatic activity can be caused by a loss of the catalytic site and/or by impaired membrane targeting of the enzyme. To investigate this, we generated two FLAG-tagged expression constructs CMV-Smpd3 and CMV-mSmpd3 encoding the WT and a mutated nSMase2 that carries the fro mutation, respectively (Fig. 2, A and B) . The constructs were used to transfect MCF-7 key determinants of ECM mineralization in an in vivo mouse model, in which Alpl forced expression in the dermis, a fibrillar, collagen-rich soft connective tissue, resulted in ectopic mineralization of the skin (Murshed et al., 2005) . Although these findings established the concurrent requirements of a mineralscaffolding protein matrix and phosphatase activities in skeletal ECM mineralization, they did not rule out the existence of other mechanisms working in concert to regulate this process. A recently identified mutation in a mouse model, which displays altered sphingolipid metabolism and poorly mineralized skeletal tissues, further enforces the likelihood that multiple mechanisms are involved in skeletal mineralization (Guenet et al., 1981; Aubin et al., 2005) .
Although initially considered as inert structural molecules, sphingolipids are now recognized as important mediators for signal transduction pathways affecting various cell functions (Merrill et al., 1997; Milhas et al., 2010; Wu et al., 2010) . Bone deformities in mouse models lacking a functional Smpd3 (sphingomyelin phosphodiesterase 3) gene underscore the importance of sphingolipid metabolism in skeletal tissues (Aubin et al., 2005; Stoffel et al., 2005) . Smpd3 encodes neutral sphingomyelinase 2 (nSMase2), a membrane-bound enzyme, which cleaves sphingomyelin to generate the lipid second messenger ceramide. Ceramide generated by sphingomyelinases or by a de novo pathway affects a wide range of cellular processes, including cell death, proliferation, and differentiation (Obeid et al., 1993; Bose et al., 1995; Richard et al., 1996; SanchezAlavez et al., 2006) .
In recent years, studies have provided useful perspectives on novel physiological roles for nSMase2 (Kolak et al., 2007; Rutkute et al., 2007; Tellier et al., 2007) . Further insight into the functions of this enzyme came with the development of animal models lacking nSMase2 activity. Currently, there are two nSMase2-deficient mouse models available: one was generated by gene targeting (Smpd3 / ), whereas the other carries a chemically induced deletion of 1,758 bp encompassing part of intron 8 and the adjacent exon 9 of the Smpd3 gene (Aubin et al., 2005; Stoffel et al., 2005 Stoffel et al., , 2007 . The latter mutation known as fragilitas ossium or fro replaces the last 33 amino acids of nSMase2, resulting in a significant reduction of total neutral sphingomyelinase activities in the tissues of the fro/fro mice (Aubin et al., 2005; Stoffel et al., 2005 Stoffel et al., , 2007 . In their recent studies, Stoffel et al. (2005 Stoffel et al. ( , 2007 characterized the skeletal phenotypes of the Smpd3 / mice as a chondrodysplasia and speculated a systemic role for neuronal Smpd3 in the regulation of the skeletal development. Although both the Smpd3 / and fro/fro mutants show similar gross skeletal abnormalities, some phenotypic differences exist between these two models. For example, the skeletal phenotype appears to be milder in Smpd3 / mice. Also, no bone or tooth mineralization defects were reported in this genetargeted model. These differences raise the possibility that additional, as yet unknown, mutations in the chemically mutagenized fro/fro model may cause the severe skeletal abnormalities.
The goals of our current study were to characterize the skeletal phenotype of fro/fro mice and to investigate the local role of Smpd3 in osteoblasts. Toward these goals, we performed a detailed characterization of the skeletal tissues in fro/fro bones of their +/fro littermates (Fig. 3, A and B) . This poor mineralization was not attributable to impaired osteoblast differentiation, as osterix (SP7) immunopositive cells were present in the cortical bones of the fro/fro mice (Fig. 3, C and D) . Also, alkaline phosphatase activity was detected within the unmineralized matrix of the fro/fro bones, further indicating that osteoblast differentiation was not affected (Fig. 3 , E and F). We next prepared total RNAs from the bones of newborn WT and fro/fro mice and examined the effects of the fro mutation on the expression of Runx2 and Atf4, encoding two key transcription factors involved in early and late osteogenic differentiation, respectively. In agreement with our histological analysis of the embryonic mice, quantitative real-time PCR (qRT-PCR) analysis showed that the expression of these osteoblast marker genes were not altered in fro/fro bones (Fig. S1 ).
Although osteoblast differentiation was not affected in fro/fro mice, we did not observe any osterix-positive cells in the marrow space in the long bones of fro/fro embryos, whereas infiltration of osteoblast progenitors into the marrow space was normal in their +/fro littermates. Instead, we observed an unusual persistence of hypertrophic chondrocyte-like cells in the cells, and the expression of both WT and mutated proteins was confirmed by Western blotting (Fig. 2 C) . As shown in Fig. 2 D, there was a marked increase in nSMase activity in cells transfected with CMV-Smpd3 but not with the CMV-mSmpd3 construct. We next examined the membrane localization of the WT and mutated nSMase2 proteins by indirect immunofluorescence and confocal microscopy using an antibody raised against the FLAG tag. Importantly, there was no alteration in the membrane localization pattern of mutant nSMase2 when compared with the WT protein (Fig. 2 E) . These data confirm that the mutation of the predicted active site is the sole reason for the loss of catalytic activity of this enzyme in fro/fro mice.
The fro mutation affects skeletal development
To investigate the effects of the fro mutation on the developing skeleton, we performed histological analysis of the long bones from embryonic day 15.5 (E15.5) +/fro and fro/fro embryos. There was an increased presence of unmineralized collagenous matrix in the cortical bones of the humerus (a representative long bone) of the fro/fro embryos in comparison to the cortical comparison to the corresponding areas of the +/fro bones confirmed that there was indeed a reduction of the apoptosis of fro/ fro hypertrophic chondrocytes (Fig. 3, G and H) .
The presence of ALPL activity in the developing fro/fro bones suggests normal PP i hydrolysis in the ECM. However, the PP i levels in the ECM may increase because of an up-regulation of Enpp1 and Ank, which encode two proteins critical for the maintenance of tissue homeostasis of this mineralization inhibitor midshaft regions of the fro/fro long bones (Fig. 3, C and D) . A possible explanation for this observation might be that the hypertrophic chondrocytes in these mutant bones were not undergoing apoptosis at a rate comparable with that of +/fro hypertrophic chondrocytes. To investigate this possibility, we performed TUNEL assay on the humerus sections from both +/fro and fro/fro embryos at E15.5. A decreased presence of TUNEL-positive nuclei in the fro/fro hypertrophic zones in the presence of ascorbic acid and -glycerol phosphate, fro/fro osteoblast cultures showed reduced mineralization in comparison to the +/fro cultures (Fig. 4 G) .
Osteoblast-specific expression of Smpd3 in fro/fro mice increases bone nSMase activity
Collectively, a decline of total nSMase activity in fro/fro bones and reduced in vitro mineralization by fro/fro osteoblasts (Fig. 4 , D and G) strongly suggest a local and specific role for nSMase2 in bone. To investigate this in vivo, we overexpressed Smpd3 specifically in the bones of fro/fro mice. For this purpose, we generated a Col1a1-Smpd3 transgene construct using a 2.3-kb Col1a1 promoter fragment, earlier shown to be specifically expressed in osteoblasts (Fig. 5 A) . Pronuclear injection of this construct into fertilized mouse eggs resulted in four founders, of which two showed bone-specific expression of the transgene. No transgene expression was detected in any other tissue in these founders (Fig. 5 B) . These founders were then mated with +/fro mice to first generate +/fro;Col1a1-Smpd3 mice, which were mated again with +/fro mice to obtain fro/fro;Col1a1-Smpd3 mice.
By visual examination, there was no gross skeletal abnormalities in the fro/fro;Col1a1-Smpd3 mice. Also, these mice survived the perinatal death routinely seen in fro/fro mice (described in Fig. 6 ). In agreement with our transgene expression data, we observed a threefold increase of total nSMase activities in the bones of newborn fro/fro;Col1a1-Smpd3 mice in comparison to the bones of fro/fro mice, whereas brain nSMase activities remained indistinguishable between these two genotypes (Fig. 5 C) . Interestingly, despite a significant increase of bone nSMase activities in fro/fro;Col1a1-Smpd3 mice, there was no detectable decrease of total bone sphingomyelin levels (Fig. 5 D) . However, an increase of total ceramide levels in the bones of fro/fro;Col1a1-Smpd3 mice was observed when compared with the fro/fro bones (Fig. 5 E) . Interestingly, we found a significant increase of several long-chain ceramide species (e.g., C16, C24, and C24:1) in the bones of the former genotype (Fig. 5 F) . No significant alterations were observed in total dihydroceramide levels in the bone extracts prepared from any of the mouse models analyzed (Fig. 5 G) . Also, several known serum parameters affecting ECM mineralization (e.g., calcium, P i , and alkaline phosphatase levels) were unaltered in the fro/fro;Col1a1-Smpd3 mice (Fig. 5, H-J) .
Finally, we compared the expression of Enpp1, Ank, Mgp, and Col1a1 by qRT-PCR in the parietal bones of newborn fro/fro and fro/fro;Col1a1-Smpd3 mice. We observed significant upregulation of Enpp1 and Ank, but not Mgp, expression. Col1a1 gene expression was mildly up-regulated in fro/fro;Col1a1-Smpd3 bones in comparison with fro/fro bones (Fig. S2) .
Normal bone mineralization in fro/fro;Col1a1-Smpd3 mice
We next examined the skeletal phenotype in fro/fro;Col1a1-Smpd3 mice. Micro-CT analysis of the humerus from 15.5-d-old fro/fro embryos showed poorly mineralized cortical bones, which were fully mineralized in the fro/fro;Col1a1-Smpd3 (Ho et al., 2000; Hessle et al., 2002) . We analyzed the expression of these two genes by qRT-PCR and found that there was in fact a mild down-regulation of Enpp1 expression in the bones of newborn fro/fro mice, whereas Ank expression was not altered (Fig. 3 I) . Also, we did not observe any up-regulation of Mgp and Col1a1 expression (Fig. 3 I) . We then used a fluorogenic sensor to measure PP i levels in the bones of adult WT and fro/fro mice. We observed that PP i was present at comparable levels in the bone samples from both genotypes (Fig. 3 J) . Collectively, these data suggest that the hypomineralization defect seen in fro/fro mice was not caused by the increase of MGP or PP i in the bone ECM.
Loss of nSMase2 in osteoblasts affects mineralization in vitro
We next examined Smpd3 expression in late-stage mouse embryos and also in tissues collected from WT mice at the preweaning age. The sense and antisense probes generated from the Smpd3 cDNA were hybridized separately on fixed wholeembryo paraffin sections prepared from E16.5 WT embryos. The in situ hybridization analysis performed with the antisense probe showed a high level of Smpd3 expression in all bone types, cartilage, and in the brain (Fig. 4 A) . A similar Smpd3 expression pattern was also observed in 2-wk-old mice (Fig. 4 B) . Next, we examined Smpd3 expression during the differentiation of MC3T3-E1 preosteoblasts cultured in the presence of ascorbic acid and -glycerol phosphate. Under these culture conditions, we observed a progressive induction of Smpd3 expression, which was down-regulated in fully mature osteoblasts (Fig. 4 C) .
A high level of expression of Smpd3 in embryonic and postnatal bones and in a differentiating osteoblastic cell line suggests a local role for this enzyme in bone. To examine whether nSMase2 deficiency in fro/fro bones causes a reduction of total nSMase activity, we prepared calvarial bone extracts from both +/fro and fro/fro mice and performed an in vitro enzymatic assay using 14 C-labeled sphingomyelin (Marchesini et al., 2003) . As a control experiment, we performed the same analysis on the extracts prepared from both +/fro and fro/fro brain tissues. As shown in Fig. 4 D, there was a comparable decrease of nSMase activities in both brain and bone extracts from fro/fro mice.
We next investigated whether a loss of nSMase2 activity affects the in vitro mineralization capacities of cultured osteoblasts. First, we transfected MC3T3-E1 preosteoblasts with siRNA oligonucleotides to knock down Smpd3 gene expression. Gene expression analysis by qRT-PCR revealed that there was an 60% reduction of Smpd3 expression in the siRNAtransfected cells (Fig. 4 E) . We cultured both control and Smpd3 siRNA-transfected cells in the presence of ascorbic acid and -glycerol phosphate to induce differentiation and mineralization. Upon culturing for 10 d in the aforementioned medium, cells were stained with Alizarin red, a calcium-binding dye. We observed reduced mineralization in the cultures with Smpd3 siRNA-transfected cells in comparison to the cultures with control siRNA-transfected cells (Fig. 4 F) . This observation was further confirmed in experiments performed with primary osteoblasts isolated from the newborn +/fro and fro/fro mice. When cultured in We observed that, as was the case in the long bones from the fro/fro mice, the marrow compartment in the long bones of fro/fro;Col1a1-Smpd3 mice was full of densely packed chondrocytes within a cartilage matrix (Fig. 6 B) . We next examined the skeleton of newborn fro/fro;Col1a1-Smpd3 mice. Osteoblastspecific expression of Smpd3 completely corrected the fro/fro skeletal abnormalities (Fig. 6 C) . X-ray analysis showed that there embryos at the same developmental stage. Interestingly, a reduced presence of mineral in the marrow compartment of both fro/fro and fro/fro;Col1a1-Smpd3 long bones was noted, indicating that the chondrocyte phenotype was largely unaffected in the latter genotype (Fig. 6 A) . The aforementioned observation was further confirmed by Alcian blue staining of the humeri sections from WT, fro/fro, and fro/fro;Col1a1-Smpd3 mice. Our current study establishes an osteoblast-specific role of Smpd3 in bone mineralization and several lines of evidence suggest that the Smpd3-encoded enzyme nSMase2 acts as a local modulator of ECM mineralization in bone. First, Smpd3 is highly expressed in bone, and its expression progressively increases as osteoblasts mature. Second, loss of Smpd3 expression in both siRNA-treated MC3T3-E1 preosteoblasts and in fro/fro primary osteoblasts causes impaired mineral deposition in cultures. Finally, osteoblast-specific expression of Smpd3 in fro/fro bones completely rescues the skeletal abnormalities. Collectively, all these findings provide unambiguous demonstration of a direct osteoblast/mineralization effect for the locally synthesized nSMase2 in osteoblasts. Furthermore, a normal skeletal appearance in fro/fro;Col1a1-Smpd3 mice suggests that the loss of nSMase2 activity in osteoblasts is the major cause of the fro/fro phenotype.
At this point, we cannot fully rule out an indirect systemic effect of nSMase2 enzymatic activity from other tissues on the developing skeleton. However, in view of our findings that osteoblast-specific expression of Smpd3 in fro/fro mice corrects the bone but not the cartilage phenotype, we do not consider this as a likely possibility. This latter finding also suggests a tissuespecific role for nSMase2 in the developing skeleton with apparent independent roles in bone and cartilage.
Both fro/fro and the gene-targeted Smpd3 / mice share similar gross skeletal abnormalities, i.e., short-limbed dwarfism, deformation of long bones, abnormally formed rib cages, and abnormalities in growth plate cartilage. However, Stoffel et al. (2005 Stoffel et al. ( , 2007 , in their gene-targeted model, did not observe bone and tooth mineralization abnormalities, which are seen in all fro/fro mice. This apparent discrepancy can be explained by differences in the analytical methods used to characterize the two mouse lines. Stoffel et al. (2005 Stoffel et al. ( , 2007 analyzed the mineralization status of the Smpd3 / mice solely by bone mineral density analysis, which determines the total bone mineral content and is not suitable for detecting an increase in unmineralized bone matrix. In contrast, we analyzed the fro/fro bones using a histomorphometric technique on undecalcified samples, commonly used to detect skeletal mineralization defects.
Although Stoffel et al. (2005 Stoffel et al. ( , 2007 suggested that the phenotypic variations in fro/fro and Smpd3 / mice can be attributable to the presence of any additional genetic alterations in the former strain, such mutations would have been fully segregated during the propagation of fro/fro mice in multiple laboratories over the last two decades. This inference, together with the observation that the fully penetrant fro/fro phenotype, including the severe hypomineralization defect, is always associated with the Smpd3 deletion mutation reported by Aubin et al. (2005) , clearly identifies the loss of nSMase2 function as the sole cause of the fro/fro phenotype. Indeed, our current data showing a complete rescue of the skeletal phenotypes in fro/fro;Col1a1-Smpd3 mice expressing Smpd3 in osteoblasts rules out the possibility of the presence of any additional mutation in fro/fro mice that may cause the observed mineralization defects.
Our results demonstrate an intrinsic loss of nSMase activity attributable to the fro mutation. The translocation of nSMase2 from the Golgi compartment to the plasma membrane was no recurrence of the skeletal abnormalities in the adult fro/fro;Col1a1-Smpd3 mice (Fig. 6 D) . Also, we observed an absence of abnormally high osteoid volume in the bones of this latter model (Fig. 6 E) .
We analyzed a total of 144 mice from the aforementioned breeding experiments, of which 17 were fro/fro. All of these mice had limb deformities, and 11 of them died perinatally. On the other hand, out of a total of 28 fro/fro;Col1a1-Smpd3 mice generated through this breeding, only three died perinatally, whereas none of them showed any kind of skeletal abnormalities (Fig. 6 F) . We tested the significance of these data using the standard Pearson's  2 test and found that for the rescue of both skeletal phenotype and perinatal death, the p-values were far below the commonly accepted 5% threshold for significance.
Discussion
Analysis of novel, genetically modified mouse models with skeletal and dental mineralization defects may provide critical information on as yet unidentified regulators of ECM mineralization and, thereby, improve our understanding of this important physiological process. Recently, a loss-of-function mutation in the Smpd3 gene has been identified in a mouse model (fro/fro), which shows severe bone and tooth mineralization defects (Guenet et al., 1981; Aubin et al., 2005) . The fro/fro skeletal abnormalities are similar to the skeletal pathology seen in patients with certain forms of osteogenesis imperfecta that do not involve any mutation in collagen genes (Glorieux et al., 2002) . As is the case with these patients, the most common parameters affecting ECM mineralization, e.g., serum calcium, P i , and alkaline phosphatase levels, are not decreased in fro/fro mice. Furthermore, when analyzed by histology, the unmineralized bone matrix appears to be secreted normally in these mice. Collectively, these observations suggest that Smpd3 might affect ECM mineralization through a novel mechanism.
In an earlier study, the skeletal phenotype of Smpd3 / mice has been described as a form of chondrodysplasia (Stoffel et al., 2005) . In agreement with this finding, we observed a significantly impaired apoptosis of hypertrophic chondrocytes, possibly caused by reduced ceramide levels during early skeletal development in fro/fro embryos. Additionally, we also observed poor mineralization of the matrix secreted by osteoblasts that severely affects the strength of the cortical bones in these embryos. This novel finding explains the long bone deformities in fro/fro mice. Our data suggest that hypomineralization of bone ECM in fro/fro mice is not caused by the elevated levels of mineralization inhibitors MGP or PP i (Fig. 3, I and J). We observed a mild down-regulation of Enpp1 in fro/fro bones, whereas both Ank and Enpp1 expressions were significantly up-regulated in the bones of fro/fro;Col1a1-Smpd3 mice. Interestingly, up-regulation of these two genes in the latter model did not prevent the rescue of the bone mineralization defects. These data suggest that there might be a compensatory interplay between the positive (nSMase2) and negative (ANK and ENPP1) regulators of bone ECM mineralization. nSMase2 and bone mineralization • Khavandgar et al.
The data we present here suggest that a local nSMase2 function is required for a normal bone mineralization and for the normal apoptosis of hypertrophic chondrocytes in the cartilage during early skeletal development (Fig. 7) . Collectively, these data demonstrate, for the first time, the tissue-specific roles for this enzyme in the developing skeleton. Further analyses of the mouse models reported here may reveal the molecular mechanisms underlying the pathophysiology of certain forms of osteomalacia and osteogenesis imperfecta in humans.
Materials and methods

DNA constructs
The DNA construct for osteoblast-specific expression of the Smpd3 transgene was generated using a 2.3-kb Col1a1 promoter fragment (Rossert et al., 1995) . A full-length Smpd3 cDNA (American Type Culture Collection) preceded by a rabbit -globin intron was inserted in between the Col1a1 promoter fragment and a SV40 polyadenylation signal. The transgene sequence was released from the plasmid backbone by SacII restriction digestion and was used for pronuclear injection. A PCR-based technique was used to introduce the fro mutation into the WT cDNA. Both WT and mutant (fro) Smpd3 cDNAs were cloned in pIRES-hrGFP-1 (Agilent Technologies).
Mice
Generation of fro/fro mice was described previously (Aubin et al., 2005) . Transgenic founders were generated by pronuclear injections at the McIntyre Cancer Center Transgenic Core Facility at McGill University following standard techniques. All mice were maintained in a pathogen-free standard animal facility, and the experimental procedures were performed following an animal use protocol approved by the Animal Care Committee of McGill University. Genotypes were determined by PCR on genomic DNAs isolated from the tail biopsies. The following primers were used for the genotyping of the fro mutation: 5-GGGACGACGTCTGCCTCAGG-3, 5-TTAGAGGTCCCAACCACAGG-3, and 5-CCCAGGTGCTGGGCA-GAAGG-3. With these three primers, it is possible to amplify specific WT (145 bp) and mutant (189 bp) DNA fragments. The Col1a1-Smpd3 transgene integration was detected using the following primer pair specific for the SV40 polyadenylation signal: 5-CAGCTCTCCATCAAGATGGT-3 and 5-CCGGTTTGGACTCAGAGTAT-3.
Gene expression analysis
Gene expression analyses were performed using a qRT-PCR system (model 7500; Applied Biosystems). Total RNA was extracted from different tissues with TRIZOL reagent (Invitrogen) and subjected to DNase I (Invitrogen) treatment. The first-strand cDNA synthesis and qRT-PCR were performed using a high-capacity cDNA reverse transcription kit (Applied Biosystems) and SYBR green quantitative PCR master mix (Maxima; Fermentas), respectively. The following primer pairs were used: 5-AGAAACCCGGTCCTCG-TACT-3 and 5-CCTGACCAGTGCCATTCTTT-3 for Smpd3 expression and its recycling back to the Golgi is a highly dynamic and regulated process. Notably, preventing nSMase2 recycling has been shown to increase nSMase activity and ceramide levels, suggesting adverse physiological consequences for alterations in localization of this enzyme (Milhas et al., 2010) . Considering the critical nature of this process, we examined whether the reduced nSMase activities in fro/fro tissues are attributable to an impaired nSMase2 localization or are caused by the loss of its catalytic activity. Our cell culture data confirm that the mutant nSMase2 localizes identically to WT nSMase2 and indicate that the reduced tissue nSMase activity in fro/fro mice is likely to be caused by the disruption of the enzyme's catalytic site.
nSMase2 cleaves sphingomyelin to generate the lipid second messenger ceramide (Merrill et al., 1997; Wu et al., 2010) . Thus, a loss of functional nSMase2 could have dual effects, i.e., both a decrease in ceramide levels and an increase in sphingomyelin levels in tissues in which Smpd3 is normally expressed. Indeed, a recent study suggested a crucial role for sphingomyelin and its degradation in bone and dentin mineralization (Goldberg et al., 2008) . However, as sphingomyelin, being an integral component of all cell membranes, is present in all tissues in relatively high amounts and because only a small fraction of it is cleaved by the nSMase2 enzymatic activity, a loss-of-function mutation in Smpd3 as such may not have any significant effects on the total tissue sphingomyelin levels. Indeed, we did not observe any difference in total sphingomyelin levels between +/fro and fro/fro bones. This observation suggests that increased sphingomyelin levels in bone attributable to the loss of nSMase2 activity may not account for the ECM mineralization defects in fro/fro mice. Although we could not detect any significant alteration in tissue sphingomyelin levels, we found a remarkable decrease of various ceramide species, particularly those with long chains, in fro/fro bones in comparison to the control +/fro bones. Currently, it is not clear how ceramide might affect bone ECM mineralization. Ceramide acting as a second messenger can affect several signaling pathways and may alter as yet unknown downstream regulators critical for bone ECM mineralization.
In conclusion, the fro/fro mice lacking a functional nSMase2 provide a unique opportunity to investigate a novel mechanism involved in vertebrate hard tissue mineralization. Figure 7 . A model depicting the local activities of nSMase2 in skeletal tissues. The cell-autonomous activity of nSMase2 in bone promotes ECM mineralization. In the cartilage, nSMase2 enzymatic activity is necessary for the normal apoptosis of hypertrophic chondrocytes.
The cross sections along the specimen long axis were reconstructed using NRecon software (SkyScan), with a distance between each cross section of 9.58 µm. Each cross section was reduced in half-size to facilitate the analysis, giving of a voxel of 9.58 × 9.58 × 9.58 µm 3 . CT-Analyser and 3D Creator software (both from SkyScan) were used to analyze and to perform 3D rendering, respectively.
Serum biochemistry
Serum calcium and P i levels were measured using commercially available kits (Diagnostic Chemicals Limited). Serum ALPL levels were measured as described previously , whereas tissue PP i levels were measured using a fluorogenic sensor following the manufacturer's instructions (Advancing Assay Technologies Bioquest, Inc.).
Sphingomyelinase assays and lipid measurements
Limbs and skullcaps were snap frozen in liquid nitrogen and crushed before further homogenization in 20 mM Tris buffer containing protease inhibitors using an autohomogenizer. Brain tissue was homogenized directly in the same buffer. Aliquots of homogenate were removed for the estimation of protein concentration by the Bradford assay. In vitro analysis of nSMase activity was performed using a mixed micelle assay as described previously (Marchesini et al., 2003) . In brief, duplicate aliquots (20-30 µg protein) of homogenate were diluted to 100 µl in neutral buffer containing 25 mM Tris, pH 7.4, 5 mM EDTA, 0.2% Triton X-100, and protease inhibitors. The reaction was started by adding 100 µl assay buffer containing 200 µM sphingomyelin, 100 µM phosphatidylserine, and 100,000 cpm 14 C-labeled methyl-sphingomyelin reconstituted in 25 mM Tris, pH 7.4, 10 mM MgCl 2 , 5 mM DTT, and 0.2% Triton X-100. After incubation for 30 min at 37°C, reactions were stopped by the addition of 1.5 ml chloroform/methanol (2:1). 400 µl of water was added, and samples were vortexed and spun at 3,000 rpm for 5 min at room temperature. Next, 800 µl of the upper phase was added to 4 ml scintillation fluid, vortexed, and counted. 10 µl assay buffer, representing 2 nmol sphingomyelin, was also counted to allow conversion of results from counts per minute to picomoles of ceramide per milligram of protein per hour. For lipid analysis by mass spectrometry, after homogenization, lysate containing 200 µg-1 mg protein was analyzed for sphingomyelin, ceramide, and dihydroceramide levels by tandem liquid chromatography/mass spectrometry as previously described (Bielawski et al., 2010) . Lipid levels were normalized to cellular protein.
Data analysis
All results are shown as means ± the standard deviation. Statistical analyses were performed by Student's t test, with P < 0.05 considered significant as indicated by a single asterisk (**, P < 0.01). Standard Pearson's  2 test was used to test the significance of the rescue of both skeletal phenotype and perinatal death.
Online supplemental material Fig. S1 shows qRT-PCR analysis of Runx2 and Atf4 expression in newborn fro/fro bones. Fig. S2 shows qRT-PCR analysis of Enpp1, Ank, Mgp, and Col1a1 expression in the bones from newborn fro/fro and fro/fro;Col1a1-Smpd3 mice. Fig. S3 shows qRT-PCR analysis of Runx2, Col1a1, Atf4, and Bglap1 expression in the control and Smpd3 siRNA-treated MC3T3-E1 cells and Runx2, Atf4, Bglap1, and Smpd3 expression in WT and +/fro mice. Online supplemental material is available at http://www.jcb .org/cgi/content/full/jcb.201102051/DC1.
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